Graefelfing, Germany – Viral technology specialist SIRION Biotech will be a high profile presence at the influential American Society of Gene and Cell Therapy (ASGCT) annual meeting, celebrating its 25th Anniversary in 2022. SIRION has consistently attended ASGCT annual meetings over many years and has frequently contributed scientific insights to the Tools & Technology conference track.
Single cell gene delivery
This year will be no exception, with SIRION CEO Dr. Christian Thirion presenting the Tools & Technology talk ‘Taking gene delivery to the single cell level’ during the Day Two afternoon session (Tuesday, May 17, 1615-16:30 hrs.). Dr. Thirion’s presentation will highlight the possibilities that stem from analysis of transduction profiles with single nuclei RNA sequencing and targeting individual cell types using nanobody retargeted AAV vectors.
USP development of recombinant AAVs for ocular applications
In addition, SIRION will contribute a Poster presentation (Tu-252, Final abstract number: 747) on ‘Upstream Manufacturing Process Development of Recombinant AAV Vectors for Ocular Applications’. This will be delivered by AV Platform Manager Dr. Helena Meyer-Berg, during the Vector ProductEngineering, Development or Manufacturing II Session in Hall D, A also on the afternoon of Day Two (Tuesday May 17, 1730-1830 hrs).
SIRION will also be an exhibitor at the ASGCT meeting, with a stand at Booth 218 at the Walter E. Washington Center. “We have been supporting this event for many years. It provide us with one of the best opportunities of the year to share knowledge and to meet partners, and potential partners,” said Dr. Carl Christel, SIRION VP for US Operations, who will also join the event team in Washington DC.